Myeloid cancers are a family of blood cancers that arise from the myeloid line of cells in the bone marrow, the branch of blood-cell production responsible for making red blood cells, platelets, and most white blood cells involved in infection-fighting. The group includes acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, and several overlap conditions. What they share is a common origin: something goes wrong in the bone marrow’s myeloid progenitor cells, causing them to grow abnormally or fail to mature into functioning blood cells. Beyond that shared root, myeloid cancers differ widely in how fast they progress, what symptoms they cause, and how they are treated.
What Makes a Cancer “Myeloid”
Blood cells are manufactured inside bone marrow by hematopoietic stem cells, which are multipotent cells capable of producing every type of blood and immune cell in the body. Early in their development, these stem cells commit to one of two main branches: the lymphoid line, which gives rise to cells like T cells and B cells, and the myeloid line, which produces a wider variety of cell types including red blood cells, platelets, neutrophils, monocytes, and other frontline immune cells.1PubMed Central. Myeloid Cell Origins, Differentiation, and Clinical Implications Cancers that arise anywhere along the myeloid branch are grouped together as myeloid neoplasms.
The core problem in myeloid cancer is a block in normal maturation. Healthy myeloid progenitor cells divide, mature, do their job, and eventually die on schedule. Genetic mutations can disrupt that process, causing immature cells to keep dividing without maturing or to resist programmed death. The specific point at which maturation gets stuck, and the specific mutation driving it, largely determine which type of myeloid cancer develops.2PubMed. Leukemia: stem cells, maturation arrest, and differentiation therapy A block very early in the myeloid pathway tends to produce a more aggressive cancer like acute myeloid leukemia, while a block that still allows partial maturation may result in a slower-moving disease like chronic myeloid leukemia.
Types of Myeloid Cancer
The major types of myeloid cancer look and behave differently enough that each has its own treatment approach and prognosis. Understanding the landscape helps, because patients often hear one of these specific names at diagnosis rather than the broad term “myeloid cancer.”
Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is the most aggressive form. Immature blast cells accumulate rapidly in the marrow and spill into the bloodstream, crowding out normal blood cells. The World Health Organization now classifies AML subtypes primarily by the genetic abnormality driving the disease rather than just by how the cells look under a microscope. One common subtype involves a mutation in FLT3, a receptor on the cell surface that, when mutated, sends constant growth signals.2PubMed. Leukemia: stem cells, maturation arrest, and differentiation therapy Another well-known subtype, acute promyelocytic leukemia, is caused by a chromosomal rearrangement that fuses two genes and prevents promyelocytes from maturing further. AML’s genetic subtype matters enormously for treatment decisions, because some subtypes respond well to targeted drugs while others require intensive chemotherapy or transplant.
Though AML can occur at any age, its molecular profile differs between children and adults. Pediatric AML tends to involve different chromosomal abnormalities and gene mutations than adult AML, even though both involve the same basic process of myeloid maturation arrest.3PubMed Central. Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia
Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) moves more slowly. It was the first cancer tied to a specific chromosomal abnormality: the Philadelphia chromosome, a swap of genetic material between chromosomes 9 and 22 that creates a fusion gene called BCR-ABL.4PubMed Central. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review That fusion gene produces an abnormal protein that acts as an always-on growth switch, pushing cells at the myelocyte stage to keep dividing.2PubMed. Leukemia: stem cells, maturation arrest, and differentiation therapy The cells still partially mature, which is why the disease is chronic rather than acute, but without treatment CML can eventually transform into an acute blast crisis that behaves much like AML.
Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS), now often called myelodysplastic neoplasms, sit in an uncomfortable middle ground. The bone marrow is abnormal and produces blood cells that are misshapen or dysfunctional, leading to low blood counts, but the disease does not always behave as aggressively as leukemia. Roughly a third of MDS patients eventually progress to AML.5The Lancet. Myelodysplastic syndromes Diagnosis rests on finding low blood counts alongside an abnormal-looking marrow, sometimes with an excess of immature blast cells.6JAMA. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review The line between high-risk MDS and early AML can be blurry, and recent studies suggest that some patients classified as MDS based on blast counts actually behave biologically like AML patients, especially when certain genetic rearrangements are present.7PubMed Central. What Is Acute Myeloid Leukemia?
Chronic Myelomonocytic Leukemia
Chronic myelomonocytic leukemia (CMML) is an overlap condition that shares features of both MDS and myeloproliferative neoplasms. Its hallmark is a persistently elevated monocyte count in the blood. CMML carries a risk of transforming into AML of roughly 15 to 30 percent over three to five years.8Haematologica. How I diagnose and treat chronic myelomonocytic leukemia Doctors further divide CMML into dysplastic and proliferative subtypes based on white blood cell count, which helps guide treatment choices and predict outcomes.9PubMed Central. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
Symptoms and How They Show Up
Myeloid cancers rarely announce themselves with a single dramatic symptom. Because the underlying problem is abnormal blood cell production, the symptoms tend to reflect whichever blood cell type is most depleted. Low red blood cells cause fatigue, shortness of breath, and pallor. Low platelets lead to easy bruising, bleeding gums, or tiny red spots on the skin. Low functional white blood cells leave patients vulnerable to infections that are unusually frequent or severe.
In AML, symptoms tend to appear suddenly and worsen quickly, sometimes within days or weeks. Different AML subtypes can produce different clinical pictures. Bleeding complications and infections are especially common in acute promyelocytic leukemia, while subtypes involving monocytic cells tend to infiltrate gum tissue and other organs more often.10Journal of Islamabad Medical & Dental College. Clinical Manifestations of Acute Myeloid Leukemia In rare cases, myeloid cancer cells can form solid tumors outside the marrow called myeloid sarcomas, which account for about 3 percent of all myeloid neoplasms. These can appear as masses in the skin, bones, or other organs, sometimes before the marrow disease is even detected.11PubMed Central. Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set
CML and MDS tend to be more insidious. Many patients are diagnosed incidentally after a routine blood test reveals an abnormal white blood cell count or unexplained anemia. In CML, an enlarged spleen from overproduction of white blood cells can cause a feeling of fullness or discomfort in the upper left abdomen. MDS patients often live with chronic fatigue and repeated infections for months before the underlying cause is identified.
Causes and Risk Factors
Most myeloid cancers arise from acquired genetic mutations, meaning mutations that develop during a person’s lifetime rather than being inherited. Several broad risk categories are well established.
Chemical and Radiation Exposures
Benzene is the most thoroughly studied chemical risk factor. A population-based study found that benzene exposure roughly doubled the odds of developing both AML and MDS, and exposure to vinyl chlorides carried a similar increase in risk.12PubMed Central. Chemical Exposures and Risk of Acute Myeloid Leukemia and Myelodysplastic Syndromes in a Population-Based Study Occupational exposures to soot, coal dust, creosote, and certain dyes were associated with even higher odds of AML specifically. Beyond benzene, ionizing radiation and treatment with certain chemotherapy drugs are the only other exposures with a firmly established causal link to leukemia, though research continues on pesticides, formaldehyde, and butadiene.13PubMed Central. Work-related leukemia: a systematic review
Therapy-related myeloid neoplasms deserve special mention. People who have previously received radiation or certain chemotherapy drugs for another cancer face an elevated risk of developing MDS or AML years later. In one study of patients who developed myeloid neoplasms after radiation therapy alone, nearly half had chromosomal losses on chromosomes 5 or 7, a pattern considered a hallmark of therapy-related disease.14PubMed Central. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy
Age and Clonal Hematopoiesis
Age is one of the strongest risk factors for myeloid cancer, and researchers now understand part of the reason. As people age, some of the stem cells in their bone marrow accumulate mutations and begin to expand at the expense of their normal neighbors. When this expansion is detectable in blood tests but has not yet caused any disease, it is called clonal hematopoiesis of indeterminate potential, or CHIP. By ages 70 to 80, roughly 10 percent of people carry detectable CHIP.15PubMed Central. Clonal Hematopoiesis of Indeterminate Potential The mutations most commonly seen in CHIP affect genes involved in regulating how DNA is read and repaired, and these same genes are frequently mutated in full-blown myeloid cancers.16Hemato. Clonal Hematopoiesis, a Risk Condition for Developing Myeloid Neoplasia Having CHIP does not mean a person will develop cancer. Most people with CHIP never do. But it represents a pre-malignant state, and people with CHIP are watched more closely if they show any blood count changes.
Inherited Predisposition
Though myeloid cancers are usually acquired, inherited genetic variants account for a meaningful minority of cases. Germline mutations in genes like RUNX1, GATA2, DDX41, and CEBPA are now recognized as specific risk factors for MDS and AML, and testing for these mutations has become more routine.17PubMed. Inherited predisposition to acute myeloid leukemia Beyond single-gene predispositions, broader familial cancer syndromes such as Li-Fraumeni syndrome and inherited bone marrow failure conditions like Fanconi anemia also raise the risk of myeloid malignancies.18PubMed Central. Hereditary myeloid malignancies Identifying a germline predisposition matters not just for the patient but for family members who might benefit from genetic counseling and monitoring.
How Myeloid Cancers Are Diagnosed
Diagnosing a myeloid cancer is rarely a single test. It typically starts with a complete blood count that shows abnormal numbers, then progresses to a bone marrow biopsy, which remains the gold standard. The biopsy provides a sample for several types of analysis that work together: examining the cells under a microscope, testing their surface markers with flow cytometry, analyzing their chromosomes, and sequencing their DNA for specific mutations.19PubMed Central. Practical diagnostic approach to assess myeloid and precursor cell neoplasms on trephine bone marrow biopsies: reflection of middle European reality This integrated approach is necessary because two myeloid cancers that look identical under the microscope can behave very differently depending on their underlying genetics, and treatment decisions increasingly hinge on which mutations are present.
After initial diagnosis and treatment, tracking tiny amounts of remaining cancer, known as measurable residual disease (MRD), has become an important tool. MRD testing can detect one leukemia cell among thousands of normal ones, and the results help doctors predict who is likely to relapse and who might benefit from more aggressive follow-up treatment, including stem cell transplant.20PubMed Central. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party For certain subtypes, like AML with an NPM1 mutation, molecular MRD monitoring during treatment can directly inform whether a transplant is needed.21PubMed. Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia
Treatment Approaches
Treatment for myeloid cancers has expanded considerably over the past two decades. The choice of therapy depends on the specific type of myeloid cancer, its genetic profile, the patient’s age, and overall fitness.
Intensive Chemotherapy and Transplant
For younger, otherwise healthy patients with AML, intensive chemotherapy remains the standard first step. The goal is to wipe out leukemia cells quickly and push the disease into remission. For patients at high risk of relapse, allogeneic stem cell transplant (receiving stem cells from a donor) is the strongest consolidation option. Transplant can reduce the risk of disease relapse by more than 60 percent compared with chemotherapy alone, largely because of a phenomenon called the graft-versus-leukemia effect, in which the donor immune cells actively attack residual cancer.22PubMed Central. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How? Transplant carries serious risks of its own, however, including graft-versus-host disease and infection, so it is reserved for situations where the relapse risk without it is high.
Lower-Intensity Regimens
Many myeloid cancer patients, particularly older adults or those with other health problems, cannot tolerate intensive chemotherapy. For these patients, the combination of a hypomethylating agent (azacitidine) with venetoclax has become a standard approach. Venetoclax targets a protein that leukemia cells use to avoid programmed cell death, and the combination has shown strong results. A meta-analysis pooling data from over 1,600 patients found that newly diagnosed AML patients treated with this combination achieved complete or near-complete remission about two-thirds of the time.23PubMed. The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis Responses were lower in patients with relapsed or refractory disease, at around 30 percent. MDS patients treated with the same combination also showed remission rates comparable to those seen in newly diagnosed AML. Research into shortened treatment cycles for venetoclax suggests that reducing the duration of each cycle may lower blood-count complications without sacrificing effectiveness.24PubMed Central. Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Targeted Therapies
CML was the first cancer to be revolutionized by targeted therapy. Imatinib, the first drug designed to block the BCR-ABL protein produced by the Philadelphia chromosome, transformed CML from a near-certain death sentence into a manageable chronic condition for most patients. The success of imatinib inspired efforts to find similar targeted drugs for other myeloid cancers. FLT3 inhibitors, designed for the subset of AML patients carrying FLT3 mutations, have improved response rates, though resistance remains a challenge. Leukemia cells can acquire additional mutations in the drug’s target that block the inhibitor from working, and second-generation FLT3 inhibitors have been developed to overcome some of these resistance mutations.25PubMed Central. Secondary mutations as mediators of resistance to targeted therapy in leukemia
Why Myeloid Cancers Resist Treatment
Drug resistance is one of the central frustrations in treating myeloid cancers, and it is not just about the cancer cells themselves. The bone marrow environment where leukemia stem cells live plays an active role. Healthy bone marrow contains a specialized niche of supportive cells that maintain normal blood stem cells. Leukemia cells hijack and remodel that niche into a shelter that protects them from chemotherapy.26PubMed Central. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang The remodeled niche sends survival signals to leukemia cells and can physically shield them from drugs, allowing a small population to survive treatment and eventually regrow.27PubMed Central. Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression This is why achieving remission on paper, where blast counts drop to normal levels, does not always mean the disease is eradicated. The leukemia stem cells hiding in the marrow niche may be dormant but alive.
Beyond the microenvironment, genetic resistance also evolves under treatment pressure. When targeted drugs kill off susceptible cells, any pre-existing subclone with a resistance mutation suddenly has a growth advantage and can expand to repopulate the disease. This is the same basic principle behind antibiotic resistance in bacteria, just applied to cancer cells. For FLT3-targeted drugs in AML, for instance, point mutations in the drug-binding site are the most frequent mechanism of acquired resistance.28PubMed Central. Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia Developing strategies that attack multiple targets at once, or that disrupt the protective marrow niche, are active areas of research aimed at cutting off these escape routes.
Experimental Frontiers in Myeloid Cancer
CAR T-cell therapy, which has been transformative for certain lymphoid cancers, has been harder to apply to myeloid cancers. The problem is one of friendly fire: the surface proteins on AML cells are also found on normal myeloid cells, so a CAR T cell engineered to attack AML would also destroy the healthy blood cells the patient needs to survive. Researchers have proposed a creative workaround: genetically editing the patient’s own stem cells to remove the target protein (like CD33) before transplant, creating a new blood system that is invisible to the CAR T cells. In animal models, this approach allowed CAR T cells to kill leukemia cells while sparing the edited healthy cells, which engrafted and functioned normally.29PubMed Central. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia The strategy remains experimental, but it illustrates the kind of gene-editing-plus-immunotherapy combination that could reshape myeloid cancer treatment if it proves safe and effective in humans.
Other approaches under investigation include bispecific antibodies that physically bridge immune cells to leukemia cells, drugs targeting the mutated metabolic enzymes IDH1 and IDH2 (already approved for certain AML subtypes), and therapies aimed at disrupting the protective bone marrow niche. The research landscape reflects a shift in how oncologists think about myeloid cancers: less as a single enemy to be bludgeoned with chemotherapy, and more as a genetically diverse ecosystem requiring precision tools and combination strategies to overcome.